Zoetis Inc. (NYSE:ZTS) Stock Position Lowered by Hutchens & Kramer Investment Management Group LLC

Hutchens & Kramer Investment Management Group LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,272 shares of the company’s stock after selling 359 shares during the period. Hutchens & Kramer Investment Management Group LLC’s holdings in Zoetis were worth $831,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ZTS. Vanguard Group Inc. grew its holdings in shares of Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares in the last quarter. Bank of New York Mellon Corp grew its position in Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after purchasing an additional 178,303 shares in the last quarter. Capital Research Global Investors increased its stake in Zoetis by 2.3% in the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after buying an additional 90,330 shares during the period. Clearbridge Investments LLC increased its stake in Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after buying an additional 166,517 shares during the period. Finally, Sarasin & Partners LLP lifted its position in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Zoetis stock traded down $0.26 during trading hours on Tuesday, reaching $192.39. 1,413,932 shares of the company were exchanged, compared to its average volume of 2,540,237. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a 50-day moving average of $188.43 and a 200 day moving average of $176.42. The firm has a market cap of $87.79 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 2.95 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.41 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.90%. Zoetis’s payout ratio is 33.14%.

Analyst Ratings Changes

Several equities analysts have recently commented on ZTS shares. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.